<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693210</url>
  </required_header>
  <id_info>
    <org_study_id>WA16291</org_study_id>
    <nct_id>NCT02693210</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      WA16291 is a Phase IIa &quot;proof-of-concept&quot; study. The primary objective of this study is to
      determine the safety and efficacy of rituximab (a B cell depleting chimeric monoclonal
      antibody) used either as monotherapy or in combination with methotrexate or cyclophosphamide
      in participants with rheumatoid arthritis who have failed prior Disease Modifying
      Anti-Rheumatic Drug (DMARD) therapy and currently have an inadequate clinical response to
      methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving American College of Rheumatology (ACR) 50 response at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving ACR 20 and ACR 70 responses at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of American College of Rheumatology Response (ACRn)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of the mean Disease Activity Scores (DAS)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Swollen Joint Count</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Tender Joint Count</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in participant's global assessment of disease activity using a Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Weeks 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in physician's global assessment of disease activity using VAS</measure>
    <time_frame>Baseline, Weeks 8, 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Health Assessment Questionnaire - Disease Index (HAQ-DI) scores</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in participant's pain measured by VAS</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-Reactive Protein (CRP) Levels</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Baseline, Weeks 12, 16, 20 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Rheumatoid factor levels at 24 weeks</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who withdrew due to insufficient therapeutic response</measure>
    <time_frame>Up to 24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group A: Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive methotrexate at dosage &gt;=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Rituximab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Rituximab and Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Methotrexate and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive &gt;=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17</description>
    <arm_group_label>Group C: Rituximab and Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Participants will receive &gt;= 10 mg/week methotrexate orally up to 24 weeks</description>
    <arm_group_label>Group A: Methotrexate</arm_group_label>
    <arm_group_label>Group D: Methotrexate and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Cyclophosphamide</intervention_name>
    <description>Participants will receive placebo in place of cyclophosphamide on Days 3 and 17</description>
    <arm_group_label>Group A: Methotrexate</arm_group_label>
    <arm_group_label>Group B: Rituximab Monotherapy</arm_group_label>
    <arm_group_label>Group D: Methotrexate and Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Methotrexate</intervention_name>
    <description>Participants will receive weekly oral placebo in place of Methotrexate</description>
    <arm_group_label>Group B: Rituximab Monotherapy</arm_group_label>
    <arm_group_label>Group C: Rituximab and Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Rituximab</intervention_name>
    <description>Participants will receive placebo in place of rituximab on days 1 and 15</description>
    <arm_group_label>Group A: Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Participants will receive 1g infusions of rituximab on Days 1 and 15</description>
    <arm_group_label>Group B: Rituximab Monotherapy</arm_group_label>
    <arm_group_label>Group C: Rituximab and Cyclophosphamide</arm_group_label>
    <arm_group_label>Group D: Methotrexate and Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with moderate to severe rheumatoid arthritis (RA) who have previously
             failed 1-5 DMARDS who currently have partial clinical response to treatment with
             methotrexate

          -  Using methotrexate as a single DMARD for at least 16 weeks, of which the last 4 weeks
             prior to baseline on a stable oral dose greater than or equal to (&gt;=) 10 milligrams
             per week (mg/week)

          -  &gt;=21 years of age

          -  Swollen Joint Count (SJC) and Tender Joint Count (TJC) &gt;= 8 (out of 66 and 68 joints
             respectively)

          -  At least 2 of the following parameters at Baseline: C- Reactive Protein &gt;= 15 mg/dL;
             Erythrocyte Sedimentation Rate &gt;= 30 millimeters per hour (mm/hr); Morning stiffness
             &gt;45 minutes

          -  Rheumatoid factor titer &gt;=20 International units per milliliter (IU/mL)

          -  Corticosteroid (less than or equal to [=&lt;] 12.5 milligrams per deciliter [mg/d]
             prednisone or equivalent) or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are
             permitted if stable for at least 4 weeks prior to baseline

        Exclusion Criteria:

          -  American Rheumatism Association (ARA) Class IV RA disease

          -  Concurrent treatment with any DMARD (apart from randomized treatment) or
             anti-TNF-alpha therapy

          -  Active infection or history of recurrent significant infection

          -  Prior history of cancer including solid tumors and hematologic malignancies (except
             basal carcinoma of the skin that have been excised and cured)

          -  Evidence of serious uncontrolled concomitant diseases such as cardiovascular disease,
             nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders

          -  Bone/joint surgery within 6 weeks prior to screening

          -  Rheumatic Autoimmune disease other than RA

          -  Active rheumatoid vasculitis

          -  Prior history of gout

          -  Chronic fatigue syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hofffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville</city>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Diepenbeek</city>
        <zip>3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34354</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-022</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-545</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cannock</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W1P 9PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stoke-on-trent</city>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 29, 2016</last_update_submitted>
  <last_update_submitted_qc>October 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

